Advances in remission induction therapy for ANCA-associated vasculitis.
Best Pract Res Clin Rheumatol
; 37(1): 101828, 2023 03.
Article
em En
| MEDLINE
| ID: mdl-37244804
ABSTRACT
Since its first description 40 years ago, huge strides have been made in the management of ANCA-associated vasculitis with improved patient outcomes. The use of cyclophosphamide and/or B-cell depleting therapy alongside glucocorticoids remains the cornerstone of therapy in organ or life-threatening disease, but recent trials have re-evaluated existing treatment strategies, alongside the development of new treatment targets. This has led to refinement of the role of plasma exchange, the use of reduced dosing of oral glucocorticoids with improved patient outcomes, as well as other treatment adjuvants/options of steroid minimization including C5a receptor antagonism and IL-5 inhibition. In this review we examine developments in remission induction therapy for ANCA-associated vasculitis.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos
/
Imunossupressores
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article